kidney disease Archives -

Manufacturing problems wreaked havoc with Mallinckrodt’s first attempt to secure FDA approval of its treatment candidate terlipressin for

Mallinckrodt tries again with kidney drug terlipressin

https://pharmaphorum.com/news/mallinckrodt-tries-again-with-kidney-drug-terlipressin/

Market Access/ News/ News

FDA knocks back Mallinckrodt’s kidney drug terlipressin

Phil Taylor kidney disease, liver disease, Mallinckrodt, regulatory, terlipressin 0 Comment

Manufacturing problems seem to have scuppered Mallinckrodt’s hopes of bringing the first approved drug to market in the

FDA knocks back Mallinckrodt’s kidney drug terlipressin

https://pharmaphorum.com/news/fda-knocks-back-mallinckrodts-kidney-drug-terlipressin/

Ardelyx’s-ambition-to-revolutionise-kidney-treatment

R&D/ Views & Analysis/ Views and analysis

Renal disease: the big picture

Catherine Longworth dialysis, kidney disease, renal disease, Sanifit 0 Comment

Renal diseases represent a formidable challenge on public health systems around the world. They are costly in terms

Renal disease: the big picture

https://pharmaphorum.com/r-d/renal-disease-the-big-picture/

News/ News/ R&D

Sanofi’s venglustat bombs again, but isn’t dead yet

Phil Taylor kidney disease, nephrology, rare disease, Sanofi, Sanofi Genzyme, venglustat 0 Comment

Shortly after failing a Parkinson’s disease study, Sanofi’s venglustat has missed the mark in another trial in autosomal

Sanofi’s venglustat bombs again, but isn’t dead yet

https://pharmaphorum.com/news/sanofis-venglustat-bombs-again-but-isnt-dead-yet/

Market Access/ News/ News

FDA sets September review date for Calliditas’ rare kidney disease drug

Phil Taylor autoimmune disease, Calliditas, fda, IGaN, kidney disease, nephrology, rare disease 0 Comment

Calliditas Therapeutics could have its first product on the market in the US this autumn, as the FDA

FDA sets September review date for Calliditas’ rare kidney disease drug

https://pharmaphorum.com/news/fda-sets-september-review-date-for-calliditas-rare-kidney-disease-drug/

Market Access/ News/ News

Calliditas eyes 2022 approval in EU for rare kidney disease drug Nefecon

Phil Taylor autoimmune disease, Calliditas, ema, kidney disease, nephrology, rare disease 0 Comment

Calliditas Therapeutics is on course to launch its first product, Nefecon for rare disease primary IgA nephropathy (IgAN),

Calliditas eyes 2022 approval in EU for rare kidney disease drug Nefecon

https://pharmaphorum.com/news/calliditas-eyes-2022-approval-in-eu-for-rare-kidney-disease-drug-nefecon/

Clear COVID health information essential for a return to healthcare as normal

News/ News/ Sales and Marketing

Pharma poised to cash in on ‘long COVID’ symptoms

Richard Staines COVID-19, heart failure, idiopathic pulmonary fibrosis, infectious diseases, kidney disease, Long COVID, mental health 0 Comment

While there’s hope that vaccination campaigns may bring the pandemic under control, “long COVID” side effects may continue

Pharma poised to cash in on ‘long COVID’ symptoms

https://pharmaphorum.com/news/big-pharma-could-cash-in-on-long/

R&D/ Views & Analysis/ Views and analysis

Ardelyx’s ambition to revolutionise kidney treatment

Catherine Longworth Ardelyx, COVID-19, hyperphosphatemia, kidney disease, kidneys, Tempanor 0 Comment

A therapy to treat hyperphosphatemia is moving closer to the market after years of development by California-based company

Ardelyx’s ambition to revolutionise kidney treatment

https://pharmaphorum.com/r-d/views-analysis-r-d/ardelyxs-ambition-to-revolutionise-kidney-treatment/

Market Access/ News/ News

Mallinckrodt’s liver disease drug terlipressin edges FDA advisory panel

Phil Taylor fda, kidney disease, liver disease, Mallinckrodt, rare disease, terlipressin 0 Comment

An FDA advisory committee has narrowly voted in favour of approval of Mallinckrodt’s terlipressin for hepatorenal syndrome type

Mallinckrodt’s liver disease drug terlipressin edges FDA advisory panel

https://pharmaphorum.com/news/mallinckrodts-liver-disease-drug-terlipressin-edges-fda-advisory-panel/

Trending

kidney disease

Login